The Centers for Medicare & Medicaid Services (opens in new tab) has finalized the Global Benchmark for Efficient Drug Pricing, or GLOBE, Model, a mandatory test that uses an international benchmark to calculate an alternative inflation rebate for certain drugs covered under Medicare Part B, according to the agency. The American Hospital Association (opens in new tab) reported that CMS finalized the model on Sept. 30, and the final rule was published in the Federal Register (opens in new tab) on Oct. 2.
The model will run for five years, from Jan. 1, 2027, through March 31, 2032, with invoicing continuing through March 31, 2034, CMS said. The final rule sets five performance years from April 1, 2027, through March 31, 2032, after an opening quarter for voluntary manufacturer submissions, and a seven-year payment period from April 1, 2027, through March 31, 2034, during which rebates are calculated, invoiced and reconciled. It will apply in randomly selected geographic areas covering about 25% of Original Medicare beneficiaries, and reduced out-of-pocket costs could begin as early as April 1, 2027, the agency said. Managed Healthcare Executive (opens in new tab) reported that the benchmark draws on prices in 19 countries and that Medicare Advantage enrollees are not included.
CMS said biosimilars and their reference biologics, drugs approved only for orphan conditions, plasma-derived products and certain cell and gene therapies are excluded. Axios (opens in new tab) reported that the final model is expected to exempt drugmakers that struck pricing deals with the Trump administration, and the American Hospital Association (opens in new tab) said CMS anticipates only four manufacturers will be required to participate.
The final rule, published in the Federal Register (opens in new tab), estimates $440 million in Medicare Part B net-spending savings over the seven-year payment period, or about $80 million a year. The proposed rule, published in December 2025, had estimated $11.9 billion in Part B net-spending savings over the model’s seven years, and the American Action Forum (opens in new tab), a center-right policy group, said both that estimate and the projected Original Medicare benefit savings fell nearly 96%. Managed Healthcare Executive (opens in new tab) reported that projected savings for beneficiaries fell to $111 million, compared with $1.4 billion in coinsurance savings alone in the proposal.
“Medicare Part B patients and American taxpayers have paid significantly more for prescription medications than people in comparable countries,” CMS Administrator Mehmet Oz said. “At CMS, we’re focused on more than promises to make healthcare more affordable — we’re taking action to pilot a new approach to lower costs and strengthen the quality of care while preserving medical innovation.”
Analysts quoted by Axios (opens in new tab) said the narrowed model would reach few products. “Even $11.9 billion in drug savings is fairly paltry over that amount of time, but $440 million is microscopic and likely means application would be limited to an extremely narrow band of products,” Capital Alpha analyst Rob Smith wrote in a note. Chris Meekins of Raymond James said fewer than five companies may be affected. “It is understandable why there was no big White House announcement of the model. CMS substantially narrowed its reach in this demo,” Meekins wrote in a note, according to Axios (opens in new tab).
Axios (opens in new tab) reported that the proposal had drawn criticism from conservative taxpayer groups and from oncology providers. The American Action Forum (opens in new tab) argued that the model’s legal footing is unsettled, noting that CMS itself describes its use of the Medicare innovation center’s testing authority for GLOBE as a “novel application.”